Last reviewed · How we verify
NVP+AZT
NVP+AZT is a combination antiretroviral therapy that inhibits HIV reverse transcriptase through two nucleoside reverse transcriptase inhibitors (NRTIs), preventing viral replication.
NVP+AZT is a combination antiretroviral therapy that inhibits HIV reverse transcriptase through two nucleoside reverse transcriptase inhibitors (NRTIs), preventing viral replication. Used for HIV-1 infection, Prevention of mother-to-child transmission of HIV (PMTCT).
At a glance
| Generic name | NVP+AZT |
|---|---|
| Also known as | Nevirapine plus zidovudine |
| Sponsor | Johns Hopkins Bloomberg School of Public Health |
| Drug class | Antiretroviral combination therapy (NNRTI + NRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV reverse transcriptase and blocks its activity. Zidovudine (AZT) is a nucleoside reverse transcriptase inhibitor (NRTI) that is incorporated into the growing viral DNA chain, causing chain termination. Together, they provide dual inhibition of reverse transcriptase through complementary mechanisms.
Approved indications
- HIV-1 infection
- Prevention of mother-to-child transmission of HIV (PMTCT)
Common side effects
- Rash (nevirapine-associated)
- Hepatotoxicity
- Anemia (AZT-associated)
- Nausea
- Headache
- Peripheral neuropathy
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- A Study of Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Reduction of Mother-to-child HIV Transmission During Breastfeeding (PHASE2)
- A Prospective Cohort of Children With HIV Infection
- ARVs to Prevent Breastmilk HIV:Viral and Immune Responses (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NVP+AZT CI brief — competitive landscape report
- NVP+AZT updates RSS · CI watch RSS
- Johns Hopkins Bloomberg School of Public Health portfolio CI